BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Verona Pharma: Post ERS Briefing - 16th September


9/11/2013 10:32:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

September 11, 2013 -- Verona Pharma is creating a specialty respiratory company focused on high value, “first-in-class” medicines for niche indications in the hospital setting. The Company currently has two innovative drugs in the mid-stages of clinical testing. The lead compound, RPL554, is an inhaled drug initially being developed for hospitalized patients with severe chronic obstructive pulmonary disease (COPD) but also has a potential in chronic treatment of the disease as well as asthma. The second drug, VRP700, is also delivered by inhalation and is being initially developed for chronic, severe cough which occurs as a symptom of a number of serious underlying lung diseases. Both molecules are believed to operate through unique mechanisms of action.

The meeting will discuss the development of Verona Pharma’s products and the key challenges facing the respiratory drug industry today in developing novel drugs that address unmet medical needs in a cost effective manner.

• Welcome and Introduction

Jan-Anders Karlsson, CEO, Verona Pharma

• News from ERS

o Anti-inflammatory and bronchodilator effect of a novel inhaled dual PDE3/4 inhibitor, RPL554, a unique “first-in-class” drug for the treatment of severe COPD

Professor Dave Singh, Professor of Clinical Pharmacology and Respiratory Medicine, Institute of Inflammation and Repair, University of Manchester

o Evaluation of the efficacy of VRP700 as a treatment for chronic severe cough

Professor Clive Page, Professor of Pharmacology and Director of the Sackler Institute of Pulmonary Pharmacology in the Institute of Pharmaceutical Science, King's College London

• Verona Pharma’s Strategy

Jan-Anders Karlsson

• Q&A

Please confirm if either you and/or a colleague would like to attend by return email or telephone Victoria Foster Mitchell on 020 3077 0486.

Victoria Foster Mitchell

Senior Consultant

Strategic Communications

F T I Consulting

+44 (0)20 3077 0486 direct

+44 (0)7816 944 230 mobile

Victoria.FosterMitchell@fticonsulting.com

Holborn Gate, 26 Southampton Buildings

London, WC2A 1PB

www.fticonsulting.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES